Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | G6PD | P11413 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30213582 | 0.93 | LMNA (0.65) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL69082 | 0.93 | LMNA (0.65) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL10013261 | 0.84 | LMNA (0.59) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL29872559 | 0.81 | LMNA (0.68) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL214157 | 0.81 | LMNA (0.68) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL67859 | 0.81 | LMNA (0.58) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL7178394 | 0.80 | LMNA (0.52) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL1487434 | 0.79 | LMNA (0.59) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL1536776 | 0.79 | ACHE (0.50) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL1245089 | 0.79 | LMNA (0.65) | LMNATRPA1CHRM1SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551927-A | Scorch-protected organic peroxide formulations | 阿科玛股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| US-20250228912-A1 | COMPOSITION AND METHODS OF TREATMENT FOR SKIN HEALTH AND SLEEP QUALITY USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2025-07-17 | — | — | US | disclosed |
| US-20240408101-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-12 | — | — | US | disclosed |
| US-20240408115-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-12 | — | — | US | disclosed |
| US-20240398903-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | disclosed |
| US-20240398735-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | disclosed |
| US-20240397990-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | disclosed |
| US-20240398745-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | disclosed |
| US-20240398838-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | disclosed |
| US-20240350374-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Xygenyx Inc. | 2024-10-24 | — | — | US | disclosed |
| US-20240335498-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Xygenyx Inc. | 2024-10-10 | — | — | US | disclosed |
| US-20240335377-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Xygenyx Inc. | 2024-10-10 | — | — | US | disclosed |
| US-20240325432-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Xygenyx Inc. | 2024-10-03 | — | — | US | disclosed |
| US-20240325292-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Xygenyx Inc. | 2024-10-03 | — | — | US | disclosed |
| US-20240299501-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | Xygenyx Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20240293347-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | Xygenyx Inc. | 2024-09-05 | — | — | US | disclosed |
| US-20230346866-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NON-MALIGNANT RESPIRATORY DISEASE | Novel Concepts Medical Ltd (IL) | 2023-11-02 | — | — | US | disclosed |
| US-20230134432-A1 | COMPOSITIONS AND METHODS FOR TREATING SOLID AND SOFT TUMORS AND PROLIFERATIVE DISEASES | Novel Concepts Medical Ltd (IL) | 2023-05-04 | — | — | US | disclosed |
| CN-115551927-A | Scorch-protected organic peroxide formulations | 阿科玛股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20210330731-A1 | TOPICAL SALVE FORMULATIONS FOR DERMAL ALKALOID DELIVERY | MARTIN ROBERT L (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408101-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT2, CPT1A, CPT1B | LMNA 2200/4885TRPA1 1744/4885CHRM1 2931/4885 |
| US-20240350374-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | MOGAT2, DGAT2, AGPAT2 | LMNA 4340/4885TRPA1 2891/4885CHRM1 1815/4885 |
| US-20240398903-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, GGH, FAH | LMNA 1859/4885TRPA1 4425/4885CHRM1 4704/4885 |
| US-20240325292-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | LPO, CENPE, ALOX15 | LMNA 938/4885TRPA1 2346/4885CHRM1 2505/4885 |
| US-20240408115-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CNR2, CNR1, HPSE | LMNA 803/4885TRPA1 1650/4885CHRM1 981/4885 |
| US-20240325432-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | CD44, ANXA1, ANXA11 | LMNA 4296/4885TRPA1 3709/4885CHRM1 3003/4885 |
| US-20240397990-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, CPT1A, CPT2 | LMNA 2368/4885TRPA1 4277/4885CHRM1 3929/4885 |
| US-20240398838-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | HPSE, HCAR1, SI | LMNA 719/4885TRPA1 1135/4885CHRM1 908/4885 |
| US-20240299501-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | SHBG, CRH, NGF | LMNA 1648/4885TRPA1 3175/4885CHRM1 926/4885 |
| US-20240335498-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | LRAT, CERT1, RBP4 | LMNA 1821/4885TRPA1 4347/4885CHRM1 2116/4885 |
| US-20240398745-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | GGH, CRAT, CPT1B | LMNA 831/4885TRPA1 1877/4885CHRM1 3161/4885 |
| US-20250228912-A1 | COMPOSITION AND METHODS OF TREATMENT FOR SKIN HEALTH AND SLEEP QUALITY USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | COL2A1, COL1A1, IGFBP1 | LMNA 447/4885TRPA1 4764/4885CHRM1 1577/4885 |
| US-20240398735-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, ABAT, CPT1A | LMNA 1717/4885TRPA1 4784/4885CHRM1 2835/4885 |
| US-20240335377-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | MTPN, MBOAT7, ALG1 | LMNA 3041/4885TRPA1 1208/4885CHRM1 2749/4885 |
| US-20240293347-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL HORMONE SUPPLEMENTATION | SHBG, CRH, S100B | LMNA 2386/4885TRPA1 3323/4885CHRM1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.